Clinical trials: sponsored by Deciphera Pharmaceuticals, LLC
- Lead sponsor (exact) Deciphera Pharmaceuticals, LLC
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Healthy Participants
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
The main purpose of this study is to determine the effect of vimseltinib on pharmacokinetics of combined oral contraceptive (COC) (ethinyl estradiol/levonorgestrel) in healthy female participants.
- Trial name
- NCT07539090
- Testing
- Vimseltinib, Combined Oral Contraceptive (COC) (ethinyl estradiol [EE]/levonorgestrel [LNG])
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Deciphera Pharmaceuticals, LLC
Healthy Male Participants
Evaluate the Effect of Vimseltinib on P-glycoprotein (P-gp) Inhibition in Healthy Male Participants
The main purpose of this study is to determine the effect of vimseltinib on pharmacokinetics of P-glycoprotein (P-gp) substrate (dabigatran) in healthy male participants. This study will last approximately 21 days.
- Trial name
- NCT07744802
- Testing
- Vimseltinib, Dabigatran
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Deciphera Pharmaceuticals, LLC
Healthy Participants
Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2)
The main purpose of this study is to evaluate the effect of multiple doses of vimseltinib on the pharmacokinetics (PK) of a clinical OCT2 substrate (metformin) in healthy male participants.
- Trial name
- NCT07158411
- Testing
- Vimseltinib, Metformin
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Deciphera Pharmaceuticals, LLC
Healthy Participants
Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate
The main purpose of this study is to determine the effect of Vimseltinib dosing on breast cancer resistance protein (BCRP) and organic-anion-transporting polypeptide 1 B1 (OAT1PB1) activity by using rosuvastatin in healthy male…
- Trial name
- NCT07158398
- Testing
- Vimseltinib, Rosuvastatin
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Deciphera Pharmaceuticals, LLC